Results 91 to 100 of about 2,862,567 (165)

Semaglutide improves MASLD and MASH in people with HIV: The SLIM LIVER study

HIV Medicine, Volume 27, Issue 10, Page 1710-1714, October 2026.
Abstract Objectives We have shown that semaglutide, a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), is a highly effective therapy for metabolic dysfunction‐associated steatotic liver disease (MASLD) in people with HIV (PWH). The OWLiver® metabolomics algorithms allow non‐invasive MASLD severity staging without liver biopsy, but the use of ...
Jordan E. Lake, Douglas W. Kitch, Amy Kantor, Rebeca Mayo, Pablo Belaunzaran‐Zamudio, Carl J. Fichtenbaum, Todd T. Brown, Kathleen E. Corey, Fred Sattler, Kristine M. Erlandson   +9 more
wiley   +1 more source

HIV-1 integrase strand transfer inhibitors with reduced susceptibility to drug resistant mutant integrases

, 2020
HIV integrase (IN) strand transfer inhibitors (INSTIs) are among the newest anti-AIDS drugs; however, mutant forms of IN can confer resistance. We developed noncytotoxic naphthyridine-containing INSTIs that retain low nanomolar IC50 values against HIV-1 ...
Valerie E Pye (8128395), Christophe Marchand (43010), Terrence R Burke (9449126), Mathieu Metifiot (1397662), Peter Cherepanov (369), Katherine Fesen (1397647), Daniel P Maskell (8307387), Xue Zhi Zhao (1397659), Yves Pommier (11158), Stephen H Hughes (9449123), Steven J Smith (9449120)   +10 more
core  

Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors

, 2011
HIV-1 integrase (IN) has been validated as an attractive target for the treatment of HIV/AIDS. Several studies have confirmed that the metal binding function is a crucial feature in many of the reported IN inhibitors.
Sechi, Mario, Rogolino, Dominga, Nicolino Pala, Carlotta Compari, Valentina Sinisi, Bacchi, Alessia, Nouri Neamati, Tino W. Sanchez, Mario Sechi, T. W. SANCHEZ, Alessia Bacchi, Carcelli, Mauro, Sanchez, Tino W., Sinisi, Valentina, N. NEAMATI, Sanchez, Tino W, V. SINISI, Mauro Carcelli, N. PALA, Fisicaro, Emilia, Dominga Rogolino, Gabriele Rispoli, M. SECHI, Emilia Fisicaro, Neamati, Nouri, Compari, Carlotta, Pala, Nicolino, Rispoli, Gabriele   +27 more
core   +1 more source

Frailty and associated clinical factors among Japanese people with HIV: A multicentre cross‐sectional study using the revised Japanese Cardiovascular Health Study criteria

HIV Medicine, Volume 27, Issue 10, Page 1670-1681, October 2026.
Abstract Objectives Frailty is relevant to HIV care across middle and later life, yet Japanese data remain limited. We evaluated frailty, prefrailty and associated factors in Japanese people with HIV using the revised Japanese Cardiovascular Health Study (J‐CHS) criteria.
Hideta Nakamura, Julian Falutz, Taro Naka, Sho Miyamori, Nanae Ikemiyagi, Kazutaka Yamaniha, Shuhei Ideguchi, Rumi Minami, Masashi Narita, Michinori Shirano, Sei Samukawa, Tomoyuki Endo, Junji Imamura, Mayumi Imahashi, Shinichiro Ueda, Kazuko Yamamoto   +15 more
wiley   +1 more source

Investigating the Role of Metal Chelation in HIV-1 Integrase Strand Transfer Inhibitors

, 2016
HIV-1 integrase (IN) has been validated as an attractive target for the treatment of HIV/AIDS. Several studies have confirmed that the metal binding function is a crucial feature in many of the reported IN inhibitors. To provide new insights on the metal
Alessia Bacchi (639107), Mario Sechi (1330632), Valentina Sinisi (2134009), Gabriele Rispoli (2131234), Mauro Carcelli (1665196), Nicolino Pala (1330635), Carlotta Compari (1717807), Tino W. Sanchez (1936552), Emilia Fisicaro (1717804), Dominga Rogolino (1665190), Nouri Neamati (275633)   +10 more
core   +1 more source

Canary in the Coal Mine? Transmitted Mutations Conferring Resistance to All Integrase Strand Transfer Inhibitors in a Treatment-Naive Patient.

, 2020
Transmitted drug resistance to the integrase strand transfer inhibitor (INSTI) class of antiretrovirals is very rare. We present a case of a treatment-naive female patient with human immunodeficiency virus harboring resistance to all INSTIs, including ...
Okeke, Nwora Lance, Hurt, Christopher B, McGee, Kara S, McKellar, Mehri S   +3 more
core   +1 more source

In Silico and In Vitro Comparison of HIV-1 Subtypes B and CRF02_AG Integrases Susceptibility to Integrase Strand Transfer Inhibitors [PDF]

, 2012
Most antiretroviral medical treatments were developed and tested principally on HIV-1 B nonrecombinant strain, which represents less than 10% of the worldwide HIV-1-infected population.
Mouscadet, Jean-François, Xiaoju Ni, Jean-François Mouscadet, Safwat Abdel-Azeim, Osamuede Osemwota, Tchertanov, Luba, Laine, Elodie, Osemwota, Osamuede, Abdel-Azeim, Safwat, Vincent Calvez, Arora, Rohit, Marcelin, Anne-Geneviève, Calvez, Vincent, Ni, Xiaoju, Rohit Arora, Elodie Laine, Anne-Geneviève Marcelin, Luba Tchertanov   +17 more
core   +1 more source

Non-integrase mechanisms for dolutegravir resistance

Retrovirology
Background Antiretroviral inhibitors that target specific aspects of human immunodeficiency virus 1 (HIV-1) replication have made a huge impact on the management of the global AIDS pandemic and the health and well-being of people that live with HIV ...
Alan N. Engelman
doaj   +1 more source

Integrase inhibitors in late pregnancy and rapid HIV viral load reduction [PDF]

, 2016
Minimizing time to Human Immunodeficiency Virus (HIV) viral suppression is critical in pregnancy. Integrase strand transfer inhibitors (INSTIs), like raltegravir, are known to rapidly suppress plasma HIV ribonucleic acid (RNA) in nonpregnant adults ...
Coleman, Jenell S, Anderson, Jean R, Yawetz, Sigal, Lazenby, Gweneth B, Seidman, Dominika, Stringer, Elizabeth M, Livingston, Elizabeth, Cates, Jordan, Miller, Emilly S, Potter, Jonell, Coleman, Jenell S., Short, William R., Rimawi, Bassam H, Short, William R, Anderson, Jean R., Miller, Emilly S., Duthely, Lunthita, Lazenby, Gweneth B., Badell, Martina L., Badell, Martina L, Stringer, Elizabeth M., Rahangdale, Lisa, Levison, Judy, Rimawi, Bassam H., Ciaranello, Andrea   +24 more
core   +1 more source

Evaluation of HIV-1 drug resistance in newly diagnosed individuals in Italy over the period 2017–2023

Journal of Global Antimicrobial Resistance
: Objective: We evaluated the prevalence of HIV-1 drug resistance in newly diagnosed individuals from 2017 to 2023, in Italy. Methods: Transmitted drug resistance (TDR) was evaluated by using the HIVdb algorithm (https://hivdb.stanford.edu/), through ...
A.C. Ka’e, F. Bassani, O. El Khalili, A. Bezenchek, F. Carli, A. Pupo, E. Gentilini Cacciola, L. Pezzati, L. Duca, I. Vicenti, W. Gennari, F. Lombardi, A. Shallvari, F. Saladini, V. Micheli, A. Cozzi-Lepri, A. Lai, M.M. Santoro, S. Rusconi   +18 more
doaj   +1 more source